Pediatric Neurology
Volume 24, Issue 5 , Pages 352-356 , May 2001

Safety, tolerability, and pharmacokinetics of remacemide in children

  • Frank M.C. Besag, MB, ChB

      Affiliations

    • St Piers Lingfield; Surrey, United Kingdom
    • Corresponding Author InformationCommunications should be addressed to: Dr. Besag; Twinwoods Health Resource Centre, Milton Road, Beds, MU41 GAT, UK
    • ,
  • Rosemary E. Newton, MB, BS

      Affiliations

    • The David Lewis Centre; Cheshire, United Kingdom
    • ,
  • Graham E. Blakey, PhD

      Affiliations

    • AstraZeneca R&D Charnwood; Leicestershire, United Kingdom
    • ,
  • Andrew D.P. Dean, PhD, MB, BCh

      Affiliations

    • AstraZeneca R&D Charnwood; Leicestershire, United Kingdom

Received 27 July 2000 ,Accepted 5 February 2001.

References 

  1. Palmer GC, Harris EW, Ray R, Stagnitto ML, Schmiesing RJ. Classification of compounds for prevention of NMDLA-induced seizures/mortality, or maximal electroshock and pentylenetetrazol seizures in mice and antagonism of MK801 binding in vitro. Arch Int Pharmacodyn Ther. 1992;317:16–34
  2. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs (A summary of the Third Eilat Conference (Royal Beach Hotel, May 27–30, 1996)). Epilepsy Res. 1996;25:299–319
  3. Jones MW, Blume W, Guberman A, et al.  Remacemide hydrochloride (300mg, 600mg, 800 mg/day) efficacy and safety versus placebo in patients with refractory epilepsy. Epilepsia. 1996;37(Suppl 5):166
  4. Leach JP, Blacklaw J, Stewart M, et al.  Mutual pharmacokinetic interactions between remacemide and carbamazepine and phenytoin but not sodium valproate in epileptic patients. Epilepsia. 1994;35(Suppl 8):52
  5. International League Against Epilepsy . International classification of epileptic seizures. Epilepsia. 1981;22:489–501
  6. Rutter M. A children’s behaviour questionnaire for completion by teachers (Preliminary findings). J Child Psychol. 1967;8:1–11
  7. Clark B, Hutchison JB, Jamieson V, Jones T, Palmer GC, Scheyer RD. Potential antiepileptic drugs. Remacemide hydrochloride. In:  Levy RH,  Mattson RH,  Meldrum B editor. Antiepileptic drugs. 4th ed.. New York: Raven Press; 1995;p. 1035–1044
  8. Nilsson L, Tomson T, Farahmand BY, Diawan V, Persson PG. Cause specific mortality in epilepsy (A cohort study of more than 9000 patients once hospitalized for epilepsy). Epilepsia. 1997;38:1062–1068
  9. Cockerell OC, Johnson AL, Sander JWAS, Hart YM, Goodridge DMG, Shorvon SD. Mortality from epilepsy (Results from a prospective population based study). Lancet. 1994;344:918–921

PII: S0887-8994(01)00256-9

Pediatric Neurology
Volume 24, Issue 5 , Pages 352-356 , May 2001

Article Tools

* Image Usage & Resolution